Table 2.
Exenatide weekly studies—CV outcomes.
| Study | N | Background OAD | Comparator | A1C reduction with exenatide (%) | Change in body weight (kg) | Change in SBP (mmHg) | Change in DBP (mmHg) | Change in Tchol (mg/dL) | Change in LDL (mg/dL) | Change in TG (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| DURATION-1 [6,42] | 295 | SU | ExBID | −1.9 | −3.7 | −4.7 | −1.7 | −11.97 | −5.01 | −15 |
| DURATION-2 [42,46] | 491 | MET | Sitagliptin, pioglitazone | −1.5 | −2.3 | −4 | None | −0.386 | −0.77 | −5 |
| DURATION-3 [29,42] | 456 | MET±SU | Insulin glargine | −1.01 | −2.6 | −3 | −1 | −4.63 | −1.93 | −4 |
| DURATION-4 [58] | 820 | None | MET, pioglitazone, sitagliptin | −1.53 | −2.0 | −1.3 | 0 | None | None | None |
| DURATION-5 [42,55] | 252 | MET+TZD | ExBID | −1.6 | −2.3 | −2.9 | 0.2 | NA | NA | NA |
| DURATION-6 [28,42] | 911 | MET, SU, TZD | Liraglutide | −1.28 | −2.68 | −2.48 | −0.49 | −2.31 | −1.93 | NA |
N, patients enrolled in the study (all studies done with exenatide 2 mg weekly); SU, sulfonylurea; ExBID, exenatide twice daily; MET, metformin; TZD, thiazolinedione; OAD, oral antidiabetic drug. Adapted from Mundil et al. and Duration trials 1–6.